Journal of Osteoporosis

Research Article

The Evidence for Efficacy of Osteoporosis Treatment in Men with Primary Osteoporosis: A Systematic Review and Meta-Analysis of Antiresorptive and Anabolic Treatment in Men

Table 3

Anti-fracture effects.
StudyVertebral fracturesNonvertebral fracturesHIP fracturesBMD
(lumbar; total hip; femoral neck)
Treatment (%)RR
(95% CI)		NNTTreatment (%)/n RR
(95% CI)		NNTTreatment (%)RR
(95% CI)		NNTMean difference % (95% CI)
or Percent change (SD)
Alendronate
Orwoll
et al. [27]		PlaceboNA (7.1)Placebo5 (5.3) 5.3 (4.3–6.3); 2.6 (1.5–3.7);
2.6 (1.5–3.7)*
Alendronate NA (0.8) Alendronate6 (4.1)
Gonnelli
et al. [28]		PlaceboNA           10; 4.2; 5.4*
AlendronateNA
Risedronate
Boonen
et al. [29]		Placebo04.5 (3.5–5.6)*; results for total hip
and femoral neck in figures
Risedronate2
Ibandronate
Orwoll
et al. [30]		Placebo2Placebo0       NA
Ibandronate1Ibandronate2
Miacakcic
Trovas
et al. [31]		Placebo2 2.47; −0.68; NA
Miacalcic1 7.13; 0.41; NA
Teriparatide
Trovas
et al. [31]		Placebo 0 Placebo 3  0.52 (3.90)
0.54 (2.70)
0.31 (4.10)
Teriparatide 20 μg 0 Teriparatide 20 μg 2 5.87 (4.50)***
1.17 (2.94)
1.53 (3.95)**
Teriparatide 40 μg 0 Teriparatide 40 μg 1 9.03 (6.46)***
2.33 (4.41)***
2.93 (6.34)***
Orwoll
et al. [32]		Teriparatide 1 (17) 0 13.5 (3.0)*** NA
Placebo 2 (17) 0 2.9 (1.5)**
*Difference between groups (95% CI); ( in favour of active treatment).
**Difference between groups (SD); in favour of active treatment.
***Difference between groups (SD); in favour of active treatment.
NA: not available.